BRCA2 and breast carcinoma: About 74% of BRCA1-related breast carcinomas, 23% of BRCA2-related breast carcinomas and 13% of sporadic breast carcinomas had triple negative phenotype lacking ER, PgR and HER2 expression (p < 0.001).